The potential of FcγRIIB in immunotherapy
We exclusively interview Dr Ali Roghanian, Associate Professor at the University of Southampton, UK, Ali is a leading researcher at the forefront of immunotherapy advancements. With a keen focus on the inhibitory IgG FcγRIIB receptor, join us as we dive into Ali’s findings, showcasing the complexities of FcγRIIB and its potential to revolutionise therapeutic approaches.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed